4-iodo-2,5-dimethoxyphenylisopropylamine has been researched along with Psychotic Disorders in 6 studies
4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist
2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.
Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with pimavanserin, a selective serotonin 5-HT(2A) receptor inverse agonist, prevented 2,5-dimethoxy-4-iodoamphetamine hydrochloride-induced head twitches, reversed the augmented locomotor response to amphetamine, and normalized prepulse inhibition in mice with amyloid pathology." | 1.38 | Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. ( Bonhaus, DW; McFarland, K; Price, DL, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wierońska, JM | 1 |
| Acher, FC | 1 |
| Sławińska, A | 1 |
| Gruca, P | 1 |
| Lasoń-Tyburkiewicz, M | 1 |
| Papp, M | 1 |
| Pilc, A | 2 |
| Pałucha-Poniewiera, A | 1 |
| Kłodzińska, A | 1 |
| Stachowicz, K | 1 |
| Tokarski, K | 1 |
| Hess, G | 1 |
| Schann, S | 1 |
| Frauli, M | 1 |
| Neuville, P | 1 |
| McFarland, K | 2 |
| Price, DL | 2 |
| Bonhaus, DW | 2 |
| Marona-Lewicka, D | 1 |
| Thisted, RA | 1 |
| Nichols, DE | 1 |
| Siuciak, JA | 1 |
| Chapin, DS | 1 |
| McCarthy, SA | 1 |
| Guanowsky, V | 1 |
| Brown, J | 1 |
| Chiang, P | 1 |
| Marala, R | 1 |
| Patterson, T | 1 |
| Seymour, PA | 1 |
| Swick, A | 1 |
| Iredale, PA | 1 |
6 other studies available for 4-iodo-2,5-dimethoxyphenylisopropylamine and Psychotic Disorders
| Article | Year |
|---|---|
The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aminobutyrates; Amphetamines; Animals; Antipsychotic Agents; | 2013 |
Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Cyclopentanes; Disease M | 2008 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System S | 2011 |
Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
Topics: Alzheimer Disease; Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Disea | 2012 |
Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
Topics: Amphetamine; Amphetamines; Animals; Apomorphine; Behavior, Animal; Cues; Discrimination Learning; Do | 2005 |
CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.
Topics: Amphetamines; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Dextro | 2007 |